Colossal Biosciences
Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.
- Location
- Dallas, USA
- Raised
- $225M
- Stage
- Series C
- Founded
- 2021
- Category
- AI
- Funding
- VC-backed
- Team
- 50-200
Funding figures as of Jul 2025 · not independently verified
Founders of Colossal Biosciences
- Ben Novak
- George Church
Investors backing Colossal Biosciences
- BOLD Capital
- Winklevoss Capital
Frequently asked questions
What does Colossal Biosciences do?
Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.
Where is Colossal Biosciences based?
Colossal Biosciences is based in Dallas, USA.
When was Colossal Biosciences founded?
Colossal Biosciences was founded in 2021.
How much has Colossal Biosciences raised?
Colossal Biosciences has raised $225M in their Series C round as of Jul 2025.
Who founded Colossal Biosciences?
Colossal Biosciences was founded by Ben Novak, George Church.
Who has invested in Colossal Biosciences?
Colossal Biosciences is backed by BOLD Capital, Winklevoss Capital.
How Colossal Biosciences would pitch themselves
○ Auto-generated01Target customer
Companies + developers adopting AI in their stack — from indie builders to enterprise ML teams working on bringing extinct species back to life.
02Problem they solve
Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platfo… The category has historically been served by tools that miss the modern workflow this product is built around.
03Key differentiator
Colossal Biosciences differentiates on bringing extinct species back to life. Backed by BOLD Capital + Winklevoss Capital, $225M raised — the company has resources + validation to compound this thesis. Founded by Ben Novak + team.
04Go-to-market strategy
Growth-stage GTM — multi-channel revenue motion (direct enterprise sales, channel partnerships, marketplace listings). Vertical specialisation + verticalised AE teams targeting enterprise + mid-market.